In vitro and in vivo Efficacy of New Blue Light Emitting Diode Phototherapy Compared to Conventional Halogen Quartz Phototherapy for Neonatal Jaundice.
10.3346/jkms.2005.20.1.61
- Author:
Yun Sil CHANG
1
;
Jong Hee HWANG
;
Hyuk Nam KWON
;
Chang Won CHOI
;
Sun Young KO
;
Won Soon PARK
;
Son Moon SHIN
;
Munhyang LEE
Author Information
1. Department of Pediatrics, Samsung Medical Center, Samsung Cheil Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. mhlee@smc.samsung.co.kr
- Publication Type:Original Article ; In Vitro ; Research Support, Non-U.S. Gov't
- Keywords:
Jaundice, Neonatal;
Phototherapy;
Rats, Gunn
- MeSH:
Animals;
Bilirubin/*metabolism;
Biochemistry/*methods;
Gallium/pharmacology;
Hematocrit;
In Vitro;
*Light;
Phototherapy/*methods;
Rats;
Rats, Gunn;
Research Support, Non-U.S. Gov't
- From:Journal of Korean Medical Science
2005;20(1):61-64
- CountryRepublic of Korea
- Language:English
-
Abstract:
High intensity light emitting diodes (LEDs) are being studied as possible light sources for the phototherapy of neonatal jaundice, as they can emit high intensity light of narrow wavelength band in the blue region of the visible light spectrum corresponding to the spectrum of maximal bilirubin absorption. We developed a prototype blue gallium nitride LED phototherapy unit with high intensity, and compared its efficacy to commercially used halogen quartz phototherapy device by measuring both in vitro and in vivo bilirubin photodegradation. The prototype device with two focused arrays, each with 500 blue LEDs, generated greater irradiance than the conventional device tested. The LED device showed a significantly higher efficacy of bilirubin photodegradation than the conventional phototherapy in both in vitro experiment using microhematocrit tubes (44 +/-7% vs. 35 +/-2%) and in vivo experiment using Gunn rats (30 +/-9% vs. 16 +/-8%). We conclude that high intensity blue LED device was much more effective than conventional phototherapy of both in vitro and in vivo bilirubin photodegradation. Further studies will be necessary to prove its clinical efficacy.
